非酒精性脂肪性肝炎治疗药物的研发现状与进展

Research and progress of pharmacotherapy of non- alcoholic steatohepatitis

非酒精性脂肪性肝炎（NASH）是脂肪变性发展到肝硬化之间的重要一步，它是目前重要的全球公共健康问题之一，并且逐渐成为全球慢性肝病的主要原因。虽然饮食和生活方式的改变为NASH一线治疗方法，但很难实施且在疾病进展中的疗效有限。运用特定药物治疗是非常必要的。本文综述了目前市场上可用的以及处于临床试验的药物，为NASH研究者或相关领域的专家提供最新研究进展信息。

Non - alcoholic steatohepatitis （NASH） is essential in the progress of steatosis development to liver cir- rhosis. As an important issue of global public health, NASH gradually becomes the world＇s leading cause of chronic liver disease. Although diet and lifestyle measures are adopted as first -line treatment approaches, they are still difficult to carry out in the treatment of NASH, with limited efficacy. Specific pharmacotherapy is necessary. This paper reviewed the drugs currently available on the market and those in clinical trials, so as to provide new information for NASH researchers or experts in the relevant field.